Johnson & Johnson reported $33.8 billion in MedTech sales for 2025, a 6.1% increase from the prior year.
Operational sales for the segment grew 5.4%, driven by cardiovascular and surgical products, according to a Jan. 21 earnings release. The company also highlighted regulatory progress on its robotic surgical system, which was submitted for review in 2025. The platform is part of J&J’s broader strategy to expand its footprint in minimally invasive and digitally integrated surgery.
J&J projects reported sales of up to $101 billion in 2026, with MedTech performance expected to remain a key driver.
